Ms. Ricciardi joined Cognition Therapeutics in March 2019 as a member of the Board of Directors. She was appointed CEO in 2020 and led the company through its initial public offering. Her career experience includes drug development and commercialization, healthcare services and genomics. She has a proven track record launching large-market therapeutics as well as negotiating financial and business development agreements, from small to multi-billion-dollar deals. Prior to her appointment as Cognition CEO, Ms. Ricciardi provided strategic counsel to biotech firms who were in the process of raising money. As senior vice president of business development at Foundation Medicine, she negotiated large-scale deals, such as the $1.03 billion transformational agreement with Roche and the acquisition of Medco by Express Scripts in 2011. At Pfizer Ms. Ricciardi was instrumental in launching major products including Norvasc, Zithromax, and Trovan, and later las SVP, led multiple global licensing efforts concentrating on international research and development and commercial partnerships. Ms Ricciardi has served as a public company Director for public, private, US, International, precommercial and commercial Boards in the life science industry. Ms. Ricciardi earned a Bachelor of Arts cum laude in English and religion from Wesleyan University and a Master of Business Administration from the University of Chicago Booth School of Management.